HIV immune and viral profiling laboratory
Multi-Omics Core
This program uses advanced lab methods to look at immune cells and viral material from people with HIV and from related vaccine or antibody studies to help explain how treatments affect the hidden viral reservoir.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11330323 on NIH RePORTER |
What this research studies
If you take part, your blood and tissue samples may be analyzed with cutting-edge methods such as single-cell RNA sequencing (which reads activity in individual cells), ATAC-seq (which shows which genes are open), and CITE-seq (which links protein and gene data). We also use spatial techniques that map where infected or immune cells sit inside tissues, helping us see how cells interact in the body. Samples from vaccine and broadly neutralizing antibody (bNAb) studies will be run through this core and combined with computational analysis to find cellular or spatial patterns tied to treatment responses. The core provides centralized laboratory and analysis support so other teams can use the data to guide better HIV vaccines and antibody therapies.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV who are enrolled in vaccine or broadly neutralizing antibody trials, or who can donate blood or tissue samples to those related studies.
Not a fit: People without HIV, or those not enrolled in the linked vaccine or antibody studies, are unlikely to directly benefit from this laboratory-focused research.
Why it matters
Potential benefit: If successful, this work could reveal cellular or tissue patterns that point the way to more effective HIV vaccines or antibody-based therapies to reduce the viral reservoir.
How similar studies have performed: Related multi-omic and spatial profiling studies have begun to reveal immune signatures linked to treatment responses, but translating those findings into cure-focused therapies is still early and experimental.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Jiang, Sizun — Beth Israel Deaconess Medical Center
- Study coordinator: Jiang, Sizun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.